Buy Flubrotizolam (FANAX) – 0.5mg for Advanced Laboratory Research in Europe

Flubrotizolam (FANAX) represents a critical thienotriazolodiazepine reference compound for contemporary forensic toxicology and analytical chemistry investigations across European laboratories. As the definitive EU source for rigorously characterised research chemicals, Pure Lab Chems .eu supplies Flubrotizolam (0.5mg) exclusively to qualified analytical chemists, biochemists, pharmacologists, and laboratory managers engaged in controlled in vitro research, mass spectral method validation, and GABA-A receptor binding studies within institutional frameworks.

Uncompromising Purity and Analytical Characterisation

Every batch of Flubrotizolam (FANAX) supplied by Pure Lab Chems .eu is guaranteed to achieve a minimum purity of ≥99.0%, as verified by reverse-phase high-performance liquid chromatography (RP-HPLC) with ultraviolet detection at 230 nm and 310 nm. This purity specification is not merely a numerical target; it represents the foundation upon which reproducible, publishable research outcomes depend. Each shipment is accompanied by a comprehensive Certificate of Analysis (CoA) that documents batch-specific HPLC chromatograms, retention time confirmation against certified reference standards, and quantitative impurity profiling with identification of any related thienotriazolodiazepine analogues or synthetic intermediates.

The CoA further includes residual solvent analysis conducted in accordance with ICH Q3C guidelines, ensuring that levels of dichloromethane, acetonitrile, methanol, and other process-related solvents remain below permitted daily exposure limits. Heavy metal content (lead, cadmium, mercury, arsenic) is verified by inductively coupled plasma mass spectrometry (ICP-MS) and reported at parts-per-million levels, typically below 10 ppm for each element. These stringent specifications distinguish our analytical-grade material from lower-grade industrial reagents that may contain uncharacterised impurities capable of confounding mass spectral interpretations or cellular assay results.

Flubrotizolam (FANAX) is supplied as compressed 0.5mg tablets or pellets exhibiting an off-white to pale beige crystalline appearance. This physical form is verified through visual inspection under controlled lighting conditions and documented in the CoA with high-resolution imagery. The tablet/pellet format ensures precise mass delivery for stock solution preparation, eliminates weighing errors associated with sub-milligram powder handling, and facilitates rapid dissolution in appropriate solvents for in vitro applications. For laboratory managers procuring reference standards for LC-MS/MS library development or proficiency testing schemes targeting novel designer benzodiazepines, this level of physical and chemical characterisation is non-negotiable.

Principal Laboratory Applications and Research Methodologies

Analytical Toxicology & Forensic Chemistry: Flubrotizolam (FANAX) serves as a certified reference material (CRM) for mass spectral library development in LC-MS/MS and GC-MS platforms used by forensic toxicology laboratories across the EU. As a potent thienotriazolodiazepine structurally related to etizolam and flubromazolam, Flubrotizolam has become increasingly relevant in drug-facilitated sexual assault (DFSA) investigations, driving under the influence of drugs (DUID) cases, and post-mortem toxicology screenings. The compound’s characteristic fragmentation pattern under electrospray ionisation (ESI) and electron impact (EI) conditions enables unambiguous identification in complex biological matrices during method validation for toxicological screenings. Laboratories participating in proficiency testing schemes utilise Flubrotizolam reference standards to calibrate instrumentation, verify extraction recovery rates, and establish limits of detection (LOD) and quantification (LOQ) for novel thienotriazolodiazepine analogues.

Chemical Synthesis & Reaction Monitoring: As a high-purity thienotriazolodiazepine building block, Flubrotizolam (FANAX) functions as a reference standard for monitoring synthetic transformations in medicinal chemistry research programmes focused on novel anxiolytic and sedative-hypnotic analogues. The compound’s well-defined IUPAC structure (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-triazolo[4,3-a]benzothiazepine) provides a stable benchmark against which reaction intermediates and analogues are compared via NMR spectroscopy and HPLC retention time matching. Synthetic chemists developing novel GABA-A receptor ligands rely on Flubrotizolam’s consistent chromatographic behaviour to validate new purification protocols and establish structure-activity relationships (SAR) within the thienotriazolodiazepine class, particularly in relation to structurally similar compounds such as etizolam, flubromazolam, and fluetizolam.link.springer+2

Pharmacological In Vitro Assays: Within controlled laboratory environments, Flubrotizolam (FANAX) is employed in receptor-binding affinity studies using recombinant GABA-A receptor subtypes expressed in mammalian cell lines. The compound serves as a radioligand displacement standard in competitive binding assays, enabling determination of Ki values for novel benzodiazepine site modulators. Cellular uptake assays utilise Flubrotizolam to investigate transporter-mediated flux across blood-brain barrier models, while metabolic stability profiling in primary hepatocyte cultures or liver microsomes establishes intrinsic clearance rates for structure-activity relationship (SAR) investigations. All such applications are strictly limited to in vitro modelling and must be conducted by qualified personnel within appropriate institutional frameworks (university, CRO, or pharmaceutical R&D).

Quality Control & Method Validation: Pharmaceutical quality control laboratories utilise Flubrotizolam (FANAX) reference standards to validate analytical methods for detecting thienotriazolodiazepine impurities and novel psychoactive substances in drug substance and drug product matrices. The compound’s well-characterised UV absorption spectrum (λmax approximately 230 nm and 310 nm) enables spectrophotometric quantification during assay development, while its stability under accelerated conditions (40°C/75% RH) supports forced degradation studies for regulatory submissions. Flubrotizolam is particularly valuable for validating methods targeting emerging designer benzodiazepines in seized materials and biological samples.

Compound Stability, Optimal Storage, and Safe Handling Protocols

Flubrotizolam exhibits moderate susceptibility to photolytic degradation and hygroscopic uptake, necessitating strict storage protocols to maintain analytical integrity over extended periods. The compressed tablets/pellets should be stored at -20°C in amber glass vials with PTFE-lined caps or in light-resistant aluminium containers with desiccant packs, protected from light and maintained under desiccated conditions (relative humidity <10%) to prevent moisture-induced degradation. For short-term use (up to 30 days), storage at +4°C in a dedicated laboratory refrigerator is acceptable, provided the container remains sealed and protected from ambient light. Long-term archival storage (-80°C under inert atmosphere) is recommended for reference standards intended for multi-year use in proficiency testing or inter-laboratory comparisons.

Critical safe handling prerequisites mandate that all manipulations of Flubrotizolam tablets/pellets occur within a certified chemical fume hood operating at a face velocity of 0.5 m/s or greater. Personnel must wear nitrile gloves (tested to EN 374 standards), safety goggles with side shields, and a laboratory coat compliant with EN 14126. Although Flubrotizolam tablets/pellets present minimal dust generation risk compared to loose powders, accidental crushing or dissolution should be avoided outside containment. For stock solution preparation, tablets/pellets should be dissolved directly in appropriate solvents: Flubrotizolam demonstrates solubility in dimethyl sulfoxide (DMSO) to 10 mM, in methanol to approximately 5 mM, and in anhydrous ethanol to 5 mM; solutions should be prepared fresh daily or stored at -20°C in amber vials for no more than 7 days to prevent oxidative degradation.

Technical Specifications and Molecular Attributes

Pure Lab Chems .eu: Your Premier EU Vendor for High-Purity Reagents

Pure Lab Chems .eu transcends the conventional supplier role to serve as an indispensable partner in European scientific rigour. Our ISO 9001-certified quality management system governs every stage of material procurement, from batch selection through final CoA issuance, ensuring that each Flubrotizolam (FANAX) batch meets the exacting standards demanded by analytical chemists and laboratory managers across all 27 EU member states. Our dedicated logistics chain employs temperature-controlled, discreet packaging with real-time tracking, guaranteeing that reference standards arrive in pristine condition regardless of destination—from Berlin to Barcelona, from Dublin to Athens.

Beyond logistics, Pure Lab Chems .eu distinguishes itself through expert customer support staffed by chemists capable of discussing analytical specifications, method validation requirements, and CoA interpretation. Whether you require guidance on HPLC method parameters for Flubrotizolam quantification or need clarification on residual solvent limits for your specific application, our technical team provides responsive, scientifically grounded assistance. We do not merely sell chemicals; we enable critical research outcomes by supplying rigorously tested, fully documented materials that form the foundation of trustworthy, reproducible science.